Allyx Therapeutics Announces License For The Treatment of Cognitive Deficits in Neurodegenerative Disorders From Bristol Myers Squibb And Yale
Allyx Therapeutics Announces License For The Treatment of Cognitive Deficits in Neurodegenerative Disorders From Bristol Myers Squibb And Yale Share Article Allyx Therapeutics expects to advance ALX-001, an mGluR5 modulator for Alzheimer’s disease, into clinical trials in 2021 NEW HAVEN, Conn. (PRWEB) January 13, 2021 Today, Allyx Therapeutics announced the completion of a license agreement with Bristol Myers Squibb to develop Allyx’s novel therapy for Alzheimer’s disease. The agreement includes a sublicense of certain ri...
Source: prweb.com